Description

Radiation therapy is the treatment of cancer and other diseases with radiation. Radiation in various forms is used to kill the cancer cells by preventing them from multiplying. Therapeutic radiology may be used to cure or control cancer, or to alleviate some of the symptoms associated with cancer. According to a report by StrategyHelix, the global radiotherapy, nuclear medicine & radiopharmaceuticals market is set to increase by US$ 12,637.9 million during 2022-2028, growing at a CAGR of 9.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for radiotherapy, nuclear medicine & radiopharmaceuticals. The global radiotherapy, nuclear medicine & radiopharmaceuticals market is segmented on the basis of product, application, and region. On the basis of product, the global radiotherapy, nuclear medicine & radiopharmaceuticals market has been segmented into radiopharmaceuticals, radiotherapy. The radiopharmaceuticals segment is estimated to account for the largest share of the global radiotherapy, nuclear medicine & radiopharmaceuticals market. By application, the global radiotherapy, nuclear medicine & radiopharmaceuticals market has been segmented into bone metastasis, endocrine tumor, hyperthyroidism, lymphoma, oncology, others. Geographically, the global radiotherapy, nuclear medicine & radiopharmaceuticals market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The radiopharmaceuticals market is further segmented into diagnostic radiopharmaceuticals, and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals segment held the largest share of the global radiotherapy, nuclear medicine & radiopharmaceuticals market in 2021 and is anticipated to hold its share during the forecast period. Furthermore, the radiopharmaceuticals by production method market has been categorized into cyclotron, generator, and nuclear reactor. The radiotherapy market is further divided into external beam radiation therapy, internal radiation therapy or brachytherapy, and systemic radiotherapy.

The global radiotherapy, nuclear medicine & radiopharmaceuticals market is highly competitive. The prominent players operating in the global radiotherapy, nuclear medicine & radiopharmaceuticals market include Accuray Inc., Advanced Accelerator Applications (Novartis International AG), Australian Nuclear Science and Technology Organisation (ANSTO), Bracco S.p.A., Cardinal Health Inc., Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., Elekta AB, GE Healthcare, IBA Molecular (IBAM), IRE – IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Nordion Inc, NTP Radioisotopes SOC Ltd., Varian Medical Systems Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the radiotherapy, nuclear medicine & radiopharmaceuticals market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: radiopharmaceuticals, radiotherapy
Application: bone metastasis, endocrine tumor, hyperthyroidism, lymphoma, oncology, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global radiotherapy, nuclear medicine & radiopharmaceuticals market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Radiotherapy, nuclear medicine & radiopharmaceuticals market overview
Part 3. Market breakdown by product
– Radiopharmaceuticals
– Radiotherapy
Part 4. Market breakdown by application
– Bone metastasis
– Endocrine tumor
– Hyperthyroidism
– Lymphoma
– Oncology
– Others
Part 5. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 6. Key companies
– Accuray Inc.
– Advanced Accelerator Applications (Novartis International AG)
– Australian Nuclear Science and Technology Organisation (ANSTO)
– Bracco S.p.A.
– Cardinal Health, Inc.
– Curium SAS
– Eckert & Ziegler Strahlen- und Medizintechnik AG
– ECZACIBASI-MONROL Nuclear Products Co.
– Elekta AB
– GE Healthcare
– IBA Molecular (IBAM)
– IRE – IRE ELiT
– Jubilant Life Sciences Ltd.
– Lantheus Holdings, Inc.
– Nordion Inc
– NTP Radioisotopes SOC Ltd.
– Varian Medical Systems Inc.
About StrategyHelix
Disclaimer